Title: The trials and tribulations of anticoagulation management during CRRT
Details: Date: 18 July 2021
Time: 1700 – 1745
Venue: Online
Synopsis: Anticoagulation management during CRRT can be a challenging task in critically ill patients. The use of Regional Citrate Anticoagulation (RCA) offers several clinical benefits for such patients on the ICU.

In this presentation our honourable speakers will offer some of their clinical management insights on the clinical application of RCA during CRRT in challenging situations through personal clinical case sharing.

Faculties:

Dr. Dmytro Khadzhynov is a consultant in the Department of Nephrology and internal Intensive Medicine of Charité University Berlin

His clinical and research interests focus on the acute kidney injury, renal replacement therapy (RRT) and regional citrate anticoagulation during RRT in critically ill patients.

Dr. Marlies Ostermann

Dr Ostermann is Consultant in Critical Care & Nephrology at Guy’s & St Thomas’ Hospital, London and Reader at King’s College London.

Her clinical interests and research interests focus on acute kidney injury, renal replacement therapy and sepsis in critically ill patients.

Dr Michael Etter (Moderator)
Senior Vice President Medical Affairs
Chief Medical Officer
Fresenius Medical Care
Medical Affairs Asia Pacific
Title: Covid-19: A Wake Up Call on Venous Thromboembolism
Details: Date: 18 July 2021
Time: 1700 – 1745
Venue: Online
Objective and Synopsis:
  • Highlight thrombotic risk in critically ill patients
  • To provide update on the risk assessment, diagnosis and management of VTE in critically ill Covid-19 patients vs other critically ill patients (non-Covid-19)
  • To highlight the guideline recommendations on timing to use pharmacological vs mechanical prophylaxis after assessing VTE and bleeding risk
  • To share the efficacy and safety (bleeding risk) of LMWH including enoxaparin in VTE management in ICU patients
Schedule:
Time Agenda Proposed Speaker
5.00pm – 5.05pm Opening Dr Yap Eng Soo
5.05pm – 5.25pm Covid-19: A Wake Up Call on Venous Thromboembolism Dr Kenneth Chan
5.25pm – 5.40pm Panel Discussion & Q&A
(talk show style)
Dr Yap and Dr Kenneth
5.40pm – 5.45pm Closing Remark Dr Yap Eng Soo
Faculties: Dr Yap Eng Soo

Dr Yap completed his medical degree at National University of Singapore. He then underwent further clinical training in Internal Medicine and Haematology in National University Hospital. He obtained his fellowship from the Royal College of Pathologists (Haematology) while spending a year doing epidemiology and statistics as a researcher at the Department of Epidemiology, Leiden University Medical Centre, Netherlands. His clinical interest is in the treatment of benign haematological conditions with a special focus on thrombosis and haemostasis. His research interests include coagulopathy in trauma, epidemiological link between arterial and venous thrombosis and medical education. Dr Yap was the immediate past President of the Singapore Society of Haematology. He is passionate about medical education and is actively involved in undergraduate and post-graduate medical education. He was previously the Haematology residency Program Director and is currently a core faculty member of the Medicine residency program, National University Hospital, Assistant Professor, Yong Loo Lin School of Medicine, National University of Singapore, as well as examiner for the National postgraduate exit examination for Haematology.

Dr Kenneth chan

Dr. Kenneth Chan is currently a Senior Consultant Respiratory Physician in private practice at Gleneagles Hospital and Mount Elizabeth Novena Hospital. Dr. Chan obtained his MBBS from the National University of Singapore in 1995, and further obtained the Master of Medicine (Internal Medicine) and MRCP (UK) in 1999. He has completed Advanced Specialty Training in Respiratory Medicine at the Singapore General Hospital in 2002 and a clinical fellowship in Critical Care Medicine at the University of Toronto, Canada in 2005. During his many years with Singapore General Hospital, he had accrued extensive experience in respiratory and critical care medicine, inclusive of highly specialized fields such as transplantation, interventional pulmonology and acute respiratory distress syndrome. He is well-versed with many cutting-edge technologies, including advanced mechanical ventilatory techniques such as high-frequency oscillatory ventilation, extra-corporeal membrane oxygenation and advanced bronchoscopic techniques such as endobronchial ultrasound. He had also undergone a fellowship at the world-renowned Thoraxklinik at Heidelberg, Germany under Prof. Felix Herth, where further he further honed his skills and knowledge in bronchoscopic procedures such as bronchial thermoplasty for asthma and bronchoscopic lung volume reduction. In addition to general respiratory medicine, Dr. Chan’s subspecialty interests are intensive care and bronchoscopy. He also has a special interest in helping patients to stop smoking. In 2012, he was the Scientific Chair for the World Congress on Tobacco and Health. Dr. Chan is an Asst Professor of Medicine at the Duke-NUS Graduate Medical School. He is also a Clinical Lecturer with the Yong Loo Lin School of Medicine. He is a past President of both the Singapore Thoracic Society and the Society of Intensive Care Medicine, Singapore. He is also a Fellow of the Academy of Medicine, Singapore, the American College of Chest Physicians and the Royal College of Physicians (UK). In addition, he holds the European Diploma in Intensive Care.

Singapore Approved Indication(s) for CLEXANE®

THERAPEUTIC INDICATIONS

Enoxaparin sodium is indicated in adults for:

  • Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery.
  • Prevention of thrombus formation in extracorporeal circulation during hemodialysis
  • Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infection or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

Dosage

Prophylaxis of venous thromboembolism in medical patients

The recommended dose of enoxaparin sodium is 4 000 IU (40 mg) once daily by SC injection.

Treatment with enoxaparin sodium is prescribed for a minimum of 6 days and continued until the return to full ambulation, for a maximum of 14 days

Please refer to full prescribing information for further information